Labcorp Holdings Inc. (LH)
After hours:
| Previous Close | 213.13 |
| Open | 213.52 |
| Bid | 198.01 x 1100 |
| Ask | 217.00 x 800 |
| Day's Range | 208.19 - 213.52 |
| 52 Week Range | 179.59 - 234.09 |
| Volume | |
| Avg. Volume | 789,580 |
| Market Cap | 17.751B |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | 45.00 |
| EPS (TTM) | 4.68 |
| Earnings Date | Jul 25, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | 2.88 (1.37%) |
| Ex-Dividend Date | May 28, 2024 |
| 1y Target Est | 241.60 |
GuruFocus.comInsider Sale: EVP, Chief Legal Officer van der Vaart Sandra D Sells Shares of Laboratory Corp ...
On May 14, 2024, van der Vaart Sandra D, Executive Vice President and Chief Legal Officer, sold 2,000 shares of Laboratory Corp of America Holdings (NYSE:LH) as reported in a recent SEC Filing.
ZacksLabcorp (LH) to Assess Preeclampsia Risk With New Test
Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.
PR NewswireLabcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of its first trimester preeclampsia screening test to be performed between 11 and 14 weeks gestation to determine the risk of developing preeclampsia before 34 weeks of pregnancy. It is the only test of its kind available in the United States and is relevant for all pregnant individuals, including those with a low- to average-risk for preeclampsia or first-time pregnancies.
